Posted on 04/08/2010 in Scientific Mast has announced the launch of a new testing system for C. difficile, a bacterium which is a common cause of hospital-acquired infections.
The new GenoType CDiff test from Hain Lifescience allows non-pathogenic, virulent and hypervirulent strains of C. difficile to be differentiated directly from stool, rectal swabs or culture.
Mast states that this new test offers a number of key advantages over traditional laboratory testing methods for the bacteria, which are time and cost-intensive as well as being imprecise about identifying specific strains.
By contrast, the GenoType test is easy to use and can provide hospitals and laboratories with the relevant data on the same day.
It stated that this level of precision is important in allowing emerging strains and infections to be identified and treated as quickly as possible.
Last month, Mast highlighted the advantages offered by its Spectrum beta lactamase set and AmpC and ESBL detection products in identifying dangerous ESBL-producing bacteria. Other news stories from 04/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
